Stillingia

Stillingia (Stillingia sylvatica L.): A Comprehensive Reference

1. Identity and Botanical Classification

Taxonomy and Nomenclature

Stillingia is a plant genus of the family Euphorbiaceae, first described for modern science as a genus in 1767. The genus is native to Latin America, the southern United States, and various islands in the Pacific and Indian Oceans. The medicinal species most relevant to Western herbal practice is Stillingia sylvatica L. (also recorded in older literature under the synonym Sapium sylvaticum Torrey). The genus Stillingia is named in honor of Benjamin Stillingfleet, an 18th-century botanist and polymath who made significant contributions to the field through his writings and influence. The genus Stillingia comprises approximately 30 species that are mainly distributed in neotropical areas.

Beyond Queen's Delight, Stillingia sylvatica is also known by several other common names, including Yaw Root and Silver Leaf. Toothleaf is an additional common name for plants in this genus. The name "Queen's Root" is derived directly from the plant part used medicinally — the root — while the name "queen's root" is thought to stem from its reputation as a "royal" remedy in the herbal apothecary, particularly in the treatment of reproductive and venereal diseases, including mercury poisoning associated with syphilis treatments.

Botanical Description and Natural Habitat

Stillingia sylvatica is a perennial plant; its stem grows 2–4 feet high, contains an acrid milky juice, and bears alternate, sessile leaves that have a somewhat leathery texture. The yellow, petalless flowers grow in a terminal spike with the female flowers at the base. The fruit is a 3-lobed capsule. The plant belongs to the Euphorbiaceae family, sharing botanical relatives with castor bean and croton.

Queen's Delight is native to sandy pine barrens and coastal regions of the southern United States, from Texas and Oklahoma across to Virginia and Florida. The plant exudes an acrid white sap when damaged, a hallmark of many spurges. This perennial herb grows wild across the southeastern United States, thriving in sandy, well-drained soils where it develops a deep taproot that concentrates the acrid, milky latex for which the genus is named. Stillingia sylvatica is considered rare in certain parts of its native range, leading to conservation efforts. Its habitat specificity makes it a plant of interest in ecological studies regarding biodiversity and the effects of habitat loss.

The Medicinal Part and Common Preparations

Herbal products typically use the large woody root and rhizome, sometimes labeled as "queen's root," "yaw root," or simply "Stillingia." Historical preparations documented in Eclectic texts included: Extract of Stillingia, Fluid Extract of Stillingia, Compound Fluid Extract of Stillingia, Compound Troches of Stillingia, Compound Liniment of Stillingia, Syrup of Queen's Root, Compound Syrup of Queen's Root, and Tincture of Stillingia.

The plant was official only in the U.S. Pharmacopeia and contains an oil and acid resin largely lost in drying; the most active preparations are made from the fresh root. Syrups and decoctions are considered of less value than the alcoholic preparations of the fresh drug, as the properties are but imperfectly extracted by water. The fresh root appears to be more toxic than the dried product.

2. Historical and Traditional Use

Indigenous North American Use

Stillingia sylvatica is native to the southeastern United States, thriving in sandy soils from Texas to Virginia. The plant was well-known among Native American tribes, who valued it for its medicinal properties long before European settlers arrived. Stillingia sylvatica was used by Native Americans for syphilis and as a cathartic, diuretic, laxative, and emetic. In large doses, it causes vomiting and diarrhea.

American Indians used the root to repel fleas; Creek Indian women were reported to consume the boiled, mashed roots after giving birth. The root was used in the southern United States for constipation, as a purgative, and to treat syphilis and liver, skin, and lung diseases. Small pieces of the root were chewed in winter to support a healthy throat and upper respiratory system.

Eclectic Medicine (19th Century)

Stillingia was a key remedy in 19th-century American Eclectic medicine, where it was widely praised for its alterative and "blood-cleansing" abilities. Eclectic physicians recommended it for syphilis, skin eruptions, swollen glands, and chronic rheumatism. It was often included in compound formulas alongside herbs like sarsaparilla, burdock, and poke root — other strong "detoxifying" and lymphatic agents.

The concept of an "alterative" was fundamental to Eclectic prescribing philosophy. In Eclectic medicine, alteratives were understood as herbs that "alter" unhealthy conditions by supporting eliminative channels, particularly the lymphatic system and skin. Traditional uses included protocols for chronic skin conditions, secondary syphilis (in historical contexts), scrofula (lymphatic tuberculosis), and what practitioners termed "constitutional weakness" characterized by sluggish elimination and recurring infections.

Stillingia is described in 19th-century Eclectic texts as alterative, and in large doses emetic and cathartic. It was extensively used by Eclectic physicians, and the report was consistently that it is one of the most efficient of the vegetable alteratives. It was believed to increase the action of the skin, with that tissue regaining tone, and free secretion; it was also thought to increase the secretions of the kidneys and bowels.

Stillingia was also historically used for bronchial congestion, with some practitioners using it as an expectorant and respiratory stimulant in cases of chronic bronchitis or "torpid" lungs. A decoction of the root was once used to treat obstinate skin problems and help clear up ulcerations and pain after mercurial treatment for syphilis, and to treat chronic laryngeal and bronchial inflammations, leucorrhea, chronic coughs, rheumatism, and chronic liver affections.

Pharmacopeial Status

The plant was included in the United States Pharmacopeia in the 19th century, highlighting its recognized medicinal value during that era. A number of 19th-century studies were published on the analysis of Stillingia root, while the plant has been largely ignored recently, even though it remained in the National Formulary until 1947.

The use of Stillingia root epitomizes the principles of Eclectic Medicine, which sought to harmonize with nature and use the body's innate healing abilities. Though the movement has largely faded, its influence persists in the continuing interest in herbal and natural remedies. The herb is potentially harsh and toxic in large or prolonged doses, especially on the gastrointestinal tract and mucous membranes, and it has largely fallen out of favor in mainstream herbal practice and is used cautiously by modern herbalists.

3. Key Chemical Constituents and Mechanisms of Action

Diterpene Esters: The Primary Bioactive Class

From roots of Stillingia sylvatica (Euphorbiaceae), eight more or less irritant Stillingia factors S1–S8 were isolated and identified as diterpene esters of the daphnane and tigliane types, carrying saturated, polyunsaturated, or hydroxylated fatty acids. These "Stillingia factors" represent the most pharmacologically significant and toxicologically important class of compounds identified from this species. The genus is known to contain diterpene esters, and this is the class that underpins both the plant's historical medical reputation and its toxicological risks.

Among the diterpene constituents, prostratin is the most extensively studied. Sources of prostratin include several plants in the Euphorbiaceae family, including Stillingia sylvatica roots. Although many phorbol esters promote tumor formation, prostratin is a non-tumorigenic compound with promise for treatment of the HIV/AIDS virus. Additional named diterpene constituents identified from the plant include gnidilatidin and gnidilatin, prostatin and prostratin, silvacrol, stillingia Factors S1–8, and stillingine.

Other Phytochemical Constituents

The root of Stillingia sylvatica contains tannin (11.6 per cent), gum, starch, volatile oil (3.25 per cent) of a strong, disagreeable odor, an acrid oil soluble in ether, an acid resin, and 5 per cent of ash. According to Bichy, an alkaloid, stillingine, is present, but this was doubted by E.G. Eberhardt. Hydrogen cyanide has also been identified. The root contains a mix of tannins, resins, volatile oil, fixed oil, and several potent diterpene esters.

Mechanism of Action: Protein Kinase C Modulation

The primary pharmacological mechanism attributed to the diterpene esters — and particularly to prostratin — is modulation of protein kinase C (PKC). Phorbol esters are tetracyclic diterpenoids generally known for their tumor-promoting activity. The phorbol esters mimic the action of diacylglycerol (DAG), an activator of protein kinase C, which regulates different signal transduction pathways and other cellular metabolic activities. They occur naturally in many plants of the families Euphorbiaceae and Thymelaeaceae.

Prostratin is a PKC activator that was extracted from tropical plants and exhibits potent anti-tumor and cell activation properties. Prostratin not only induces HIV expression from latently infected cells through phosphorylation and degradation of IκBα, leading to the rapid nuclear translocation of NF-κB, but also inhibits HIV entry by interacting with a cellular target necessary for viral entry, displaying potent antiviral activity against different strains of HIV-1 and SIV.

The PKC pathway plays an important role in cellular latency reactivation via NF-κB signaling as well as by a positive transcription elongation factor b (P-TEFb)-dependent manner. It is critical to note, however, that while prostratin and related diterpenes from Stillingia species show interesting antiviral and anticancer activity in vitro, these studies use isolated, often synthetic compounds at tightly controlled doses — not crude Stillingia root preparations.

Mechanisms Underlying Irritancy and Toxicity

The plant contains diterpene esters, which can be irritating and harmful, illustrating the fine line between medicine and poison in traditional herbal remedies. Stillingia contains diterpene esters that cause mucosal irritation and skin eruptions. The dual nature of these compounds — potentially therapeutic at precisely controlled doses of isolated molecules, but irritant and co-carcinogenic as components of the crude plant — is a defining pharmacological feature of the genus and a central safety concern.

4. Scientific Evidence by Area of Use

4.1 Antiviral Activity (HIV and Chikungunya)

The most scientifically substantiated area of research involves isolated diterpenoids from the Stillingia genus (not necessarily S. sylvatica specifically) and their antiviral properties, conducted entirely at the preclinical level.

Stillingia lineata (Chikungunya virus and HIV, in vitro): In an effort to identify new potent and selective inhibitors of chikungunya virus and HIV-1 and HIV-2 virus replication, the endemic Mascarene species Stillingia lineata was investigated. LC/MS and bioassay-guided purification of the EtOAc leaf extract using a chikungunya virus-cell-based assay led to the isolation of six new and three known tonantzitlolones possessing the rare C20-flexibilane skeleton, along with tonantzitloic acid and several tigliane-type diterpenoids. These compounds were investigated for selective antiviral activity against chikungunya virus (CHIKV), Semliki Forest virus, Sindbis virus, and — for selected compounds — the HIV-1 and HIV-2 viruses. This study, published in the Journal of Natural Products (2015), represents rigorous phytochemical and cell-based antiviral screening; no human trials arose from it.

Stillingia loranthacea (Zika virus, in vitro): A study representing the first phytochemical analysis of Stillingia loranthacea described new terpenoids obtained from the root bark, including loranthones A and B and tigliane and flexibilene diterpenes. The cytotoxicity of these compounds was evaluated against Vero cells, and antiviral activity was tested against an epidemic Zika virus (ZIKV) strain circulating in Brazil. Again, this was a cell-based study only.

Prostratin and HIV latency reversal (in vitro and ex vivo): Cure strategies to eliminate latent HIV reservoirs require reactivation of proviral gene expression. In one study, optimal concentrations of PKC agonist candidates — including prostratin — were tested to reactivate HIV latency in vitro and in CD4 T cells from SIV-infected macaques. The results showed that PKC agonists increased cell activation with different degrees of latency reactivation, concomitant with reduced levels of histone methylation. With increasing concentrations, prostratin treatment rapidly reduced cell survival and cell activation. Activation of the NF-κB signaling pathway by PKC agonists is a potent mechanism for HIV latency disruption in vitro; however, significant toxicity risks and the lack of evidence supporting their activity in vivo have limited further evaluation of PKC agonists as HIV latency-reversing agents in cure strategies.

Evidence strength: All antiviral evidence is preclinical (in vitro and, to a limited extent, ex vivo). No human clinical trials have been conducted with crude Stillingia root or its extracts for any antiviral indication. Research on prostratin as a candidate molecule targets it as an isolated, often chemically synthesized compound — not as a herbal preparation.

4.2 Anticancer Activity

Stillingia is known to contain chemicals called diterpene esters, toxic irritants that can cause swelling and inflammation. One lab experiment suggested that diterpene esters can halt the growth of cancer cells, but stillingia itself has not been evaluated. The ambivalence of the diterpene ester class is well-established: phorbol esters themselves do not induce tumors but promote tumor growth following exposure to subcarcinogenic doses of carcinogens. They can thus be regarded as co-carcinogens. Meanwhile, cytotoxic, proteolytic, and antifungal activities have been reported for several Stillingia species.

An Office of Technology Assessment report noted that components of stillingia — specifically gnidilatidin — have shown positive antitumor activities in animal tests. Nevertheless, there is no evidence to support the use of stillingia to treat cancer, infections, or other medical conditions, according to Memorial Sloan Kettering Cancer Center.

Hoxsey Herbal Therapy: Stillingia root is one of the ingredients in Hoxsey Herbal Therapy, which is promoted as an alternative cancer treatment. The liquid tonic component of Hoxsey herbal treatments contains licorice, red clover, burdock root, Stillingia root, barberry, cascara, prickly ash bark, buckthorn bark, and potassium iodide for internal consumption. Reviews by major medical bodies, including the U.S. Food and Drug Administration (FDA), the National Cancer Institute, the American Cancer Society, M.D. Anderson Cancer Center, and Memorial Sloan-Kettering Cancer Center, have found no evidence that Hoxsey Therapy is an effective treatment for cancer. The sale or marketing of the Hoxsey Method was banned in the United States by the FDA on September 21, 1960 as a "worthless and discredited" remedy.

In vitro and animal studies conducted with individual components of the Hoxsey formula — including stillingia — indicate possible anti-tumor and immunostimulant properties, but their concentrations and activity in the context of the formulation remain unestablished. No clinical data support the alleged benefits of Hoxsey's herbal mixture or its ingredients for treating cancer patients. The scientific literature is scant and only shows that specific molecules extracted from plants in Hoxsey's mixture showed anticancer properties in laboratory studies; there are no studies in humans.

Evidence strength: Anticancer evidence is limited to in vitro and animal studies of isolated diterpenoid constituents, with the compound-level findings complicated by the same class of molecules being associated with tumor promotion at different doses or in different structural configurations. No clinical evidence exists.

4.3 Skin Conditions

The root has been used in traditional medicine to treat syphilis, bronchitis, constipation, hemorrhoids, and skin conditions. Eclectic physicians used the herb specifically for chronic and "scrofulous" skin eruptions, and stillingia, either alone or in combination with other alteratives, was employed by hundreds of physicians in the treatment of scrofulous disease in all its forms. However, there are no clinical data to support the use of this herb for any of the proposed claims. All documentation of skin-related benefits is historical and anecdotal.

4.4 Respiratory Conditions

Traditional use for respiratory complaints is well-documented in the historical record. Stillingia liniment, both externally and internally, was described as an excellent remedy in various forms of croup. Specific indications in Eclectic texts included laryngeal irritation with paroxysmal, hoarse, croupous cough; irritation of the superior pharynx just behind the fauces with cough; and mucous membranes that were tumid, red, and glistening with scanty secretion. No clinical trials have investigated these indications in human subjects, and there are no clinical data to support the use of this herb for any of the proposed claims.

4.5 Lymphatic System and "Alterative" Function

The "alterative" category — encompassing effects on lymphatic drainage, skin secretion, and general eliminative function — was the central rationale for Eclectic use. Stillingia is described as alterative and, in large doses, emetic and cathartic; it was employed for its alterative properties and was extensively used by Eclectic physicians for decades. It was believed to increase the action of the skin and to increase the secretions of the kidneys and bowels in a marked manner. While some researchers have explored hepatic cytochrome P450 pathway interactions, from a modern pharmacology perspective, there is no clear, beneficial "mechanism of action" for the whole plant that is supported by human research.

5. Body Systems and Health Areas Associated with Stillingia

Based on traditional use and available (largely preclinical) science, Stillingia sylvatica has been historically associated with the following body systems:

• Lymphatic system: Historically used as a "lymphatic cleanser" and alterative agent, with traditional use for scrofula (lymphatic tuberculosis) and swollen lymph glands.
• Skin: Used traditionally in Native American medicine and by the Eclectic physicians to support skin health, particularly for chronic and eruptive conditions.
• Respiratory system: Used by Eclectic physicians to support the upper respiratory system, including for bronchitis and croup-like conditions.
• Gastrointestinal system: Used historically for occasional constipation, and described as purgative and emetic in higher doses.
• Liver: Used in the southern United States for liver diseases.
• Immune and anti-infective: Historically applied in syphilis and other chronic infectious presentations; isolated constituents (prostratin) studied in vitro for HIV-relevant immune modulation.

6. Dosage Forms and Reported Dosages

The following dosage information derives from historical pharmacopeial and Eclectic medical sources. No modern clinical trials have established safe or effective dosages, and the historical figures reflect practices from a time before rigorous safety evaluation.

• Fluid Extract (Fluidextractum Stillingiae): Dose: 1–2 mL (15–30 minims), prepared in diluted alcohol as menstruum.
• Decoction: Dose: 1–2 fluid ounces (30–60 mL). Prepared by boiling 1 teaspoon of dried rootstock in 1 cup of water; taken as 1 cup per day, a mouthful at a time.
• Tincture: Dose of the tincture: from ½ fluid drachm to 1 fluid drachm. A tincture dose of 5 to 20 drops is also cited in historical references.
• Specific Stillingia (concentrated preparation): Dose of specific stillingia: 1 to 20 drops.
• Compound Fluidextract: Dose: 2–4 mL.
• Compound Syrup: Dose: 4–15 mL.
• Tincture (historical Eclectic range): Dose: 2–8 mL.

Despite its popularity in early American herbalism, stillingia was known to cause side effects such as nausea, vomiting, burning in the throat, or diarrhea, particularly if used in high doses or in its fresh form. As a result, it was traditionally dried and combined with soothing demulcents to mitigate its intensity.

7. Safety Considerations and Interactions

Diterpene Ester Toxicity and Irritancy

Stillingia contains diterpene esters that cause mucosal irritation and skin eruptions. Other reported toxicities include vertigo, diarrhea, nausea, vomiting, muscle ache, pruritus, cough, fatigue, and sweating. These effects are mechanistically linked to the PKC-activating and inflammatory properties of the daphnane- and tigliane-type diterpene esters.

Tumor Promotion Risk

Stillingia root is a purgative and irritant product that should be avoided because of a high likelihood of tumor promotion and documented severe irritancy to skin. The presence of phorbols (protein kinase C activators) suggests mutagenicity is possible. This concern is structural: phorbol esters are tetracyclic diterpenoids generally known for their tumor-promoting activity. They mimic the action of diacylglycerol (DAG), an activator of protein kinase C, which regulates different signal transduction pathways and other cellular metabolic activities. Phorbol esters themselves do not induce tumors but promote tumor growth following exposure to subcarcinogenic doses of carcinogens. They can thus be regarded as co-carcinogens.

Fresh vs. Dried Root

Particular caution is warranted with the fresh root, which appears to be more toxic than the dried product. The plant contains an oil and acid resin largely lost in drying; the most active preparations are made from the fresh root. This means the fresh plant concentrates the most biologically active — and most irritant and potentially toxic — constituents.

Cyanogenic Compounds

The diterpene esters in Stillingia are strongly irritating to skin and mucous membranes and, in animal and cell studies, can act as tumor promoters. Hydrogen cyanide has also been detected in related stillingia oils, reinforcing concerns about toxicity.

High-Dose Effects

Stillingia sylvatica was used by Native Americans as a cathartic, diuretic, laxative, and emetic. In large doses, it causes vomiting and diarrhea. In large doses, it is emetic and cathartic. This dose-response relationship was recognized from the earliest records.

Pregnancy and Lactation

Stillingia is contraindicated for use during pregnancy or lactation, as noted in contemporary herbal product labeling. No specific clinical studies characterizing the risks in these populations have been identified, but the potent biological activity of its constituents — including PKC-activating diterpene esters — represents a theoretical concern.

Drug Interactions

No rigorously characterized pharmacokinetic drug–herb interactions with Stillingia sylvatica as a whole herb have been established in clinical studies. The drugs.com monograph on Queen's Delight states that stillingia should not be ingested or used topically in human medicine. The presence of PKC-activating phorbol-type compounds raises theoretical concern about interactions with agents that modulate the same signaling pathways, but no such interactions have been confirmed in humans. Experimental use of prostratin analogs in HIV latency reversal is studied in conjunction with antiretroviral therapy, but this is for isolated, chemically characterized compounds — not crude botanical preparations.

Overall Risk-Benefit Assessment from Authoritative Sources

There are no clinical trials demonstrating that Queen's Delight, as an herb, improves health outcomes for any condition. Queen's Delight is best understood today as a historically important but high-risk, irritant botanical rather than a proven wellness supplement. Preliminary laboratory studies have investigated its anti-inflammatory and immunomodulatory properties, suggesting potential for supporting immune function and reducing inflammation. However, there is a notable lack of large-scale, well-controlled clinical trials validating these effects in humans. Modern scientific research into Stillingia root is exploring its constituents and potential health benefits, particularly its anti-inflammatory and anticancer properties. However, much of its traditional use remains to be validated by rigorous scientific investigation.

References

• Memorial Sloan Kettering Cancer Center — Stillingia Monograph
• Drugs.com Natural Product Professional Monograph: Queen's Delight (Stillingia sylvatica)
• Wikipedia — Stillingia (genus overview)
• Wikipedia — Hoxsey Therapy
• Memorial Sloan Kettering Cancer Center — Hoxsey Herbal Therapy
• Science Feedback — The Hoxsey herbal mixture doesn't cure cancer
• Adolf W. & Hecker E. (1980) — New irritant diterpene-esters from roots of Stillingia sylvatica L. (Euphorbiaceae). Tetrahedron Letters (via ScienceDirect)
• Olivon F. et al. (2015) — Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata. Journal of Natural Products, 78(5):1119–1128
• PubMed: PMID 25946116 — Olivon et al., J Nat Prod 2015
• de Abrantes R.A. et al. (2019) — Tri- and Diterpenoids from Stillingia loranthacea as Inhibitors of Zika Virus Replication. Journal of Natural Products
• Tonantzitlolones from Stillingia lineata ssp. lineata as potential inhibitors of chikungunya virus (ScienceDirect)
• LC–MS method for detecting prostratin in plant extracts (ScienceDirect)
• Nathalie Roche et al. (2016) — In vitro effects of small-molecule PKC agonists on HIV latency reactivation. Scientific Reports
• PMC5150635 — In vitro effects of PKC agonists on HIV latency reactivation
• Goel G. et al. (2007) — Phorbol Esters: Structure, Biological Activity, and Toxicity in Animals. International Journal of Toxicology
• PubMed: PMID 17661218 — Phorbol esters: structure, biological activity, and toxicity in animals
• King's American Dispensatory — Stillingia (Eclectic historical text, Henriette's Herbal)
• Scudder (1898) — Stillingia (Eclectic historical text, Henriette's Herbal)
• Manual of Pharmacology — Stillingia (ChestOfBooks historical materia medica)
• Medicinal Herb Info — Stillingia
• Caring Sunshine — Stillingia ingredient overview
• PMC9090023 — Concentrated Vegetable Medicines (1876, historical primary source)
• VitaLibrary — Queen's Delight: Evidence-Based Guide
• Springer — Pro-Inflammatory, Tumour-Promoting and Anti-Tumour Diterpenes of the Plant Families Euphorbiaceae and Thymelaeaceae